NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

TuHURA Biosciences, Inc. (HURA) Stock Analysis

TuHURA Biosciences, Inc. (HURA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HURA

$2.09

+$0.32 (+18.47%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HURA with… →

HURA Key Statistics

As of Oct 21, 2026
Trading
Open
$1.74
Previous Close
$1.76
Day's Range
1.71–2.11
52-Week Range
0.41–3.43
Volume
1.04M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.84
Valuation
Market Cap
$132.87M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.54
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$30.05M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.73M
1-Year Return
−9.74%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
219.82K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HURA closed at $2.09, −9.74% over 1 year.

TuHURA Biosciences, Inc. (HURA) has a market capitalization of $132.87M.

In fiscal 2025, HURA reported revenue of $0.00.

HURA Stock Return by Calendar Year

TuHURA Biosciences, Inc. (HURA) 10-year return: what $10,000 became

1 year
$10,000 $9,026
−9.74%
5 years
$10,000 $13
−99.87%
10 years
$10,000 $0.23
−99.998%

If you had invested $10,000 in TuHURA Biosciences, Inc. (HURA) 10 years ago, at the close on October 21, 2016, it would have been worth $0.23 at the close on October 21, 2026: −99.998% in total, −65.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+175.43%
2025−81.49%
2024−31.26%
2023−97.53%
2022−72.98%
2021−60.16%
2020+85.51%
2019−79.82%
2018−68.62%
2017−65.82%
2016 (partial year)−51.68%

As of October 21, 2026.

HURA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$30.05M—
2024$0.00−$21.68M—
2023$0.00−$29.32M—
2022$0.00−$9.37M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$27.29M−$30.05M—
2024$0.00—−$17.15M−$21.68M—
2023$0.00—−$13.17M−$29.32M—
2022$0.00—−$9.72M−$9.37M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values TuHURA Biosciences, Inc. (HURA) at $132.87M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 22.

The most recent close on file for HURA is $2.09, dated October 21, 2026. That is +$0.32 (+18.47%) against the previous close. Over the past 52 weeks the price has ranged from $0.41 to $3.43. The latest close sits 408.54% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $30.05M. Trailing earnings per share are −0.54.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −9.74%. Across 10 years the annualized return works out at −65.68%. The reported beta is −0.84. Annualized volatility over the trailing 10 years is 128.56%.

Growth & Income

No dividend is on file for HURA.

Across the complete calendar years on file, 2020 returned +85.51% and 2023 returned −97.53%. Of the 9 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is +175.43% year to date.

Peer Comparison

TuHURA Biosciences, Inc. (HURA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TuHURA Biosciences, Inc. HURA $132.87M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. TuHURA Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Visit website →